Senseonics Holdings, Inc.

Canaccord Genuity is pleased to announce that on March 23, 2016, it completed an underwritten initial public offering of common stock for Senseonics Holdings, Inc. (NYSE-MKT: SENS).  The company issued a total of 15,800,000 shares of common stock at a price of $2.85 per share.  In addition, the underwriters have been granted a 30-day option to purchase up to an additional 2,370,000 common shares at the initial public offering price.  Canaccord Genuity acted as a Joint Bookrunning Manager for the offering.  Senseonics intends to use the net proceeds from this offering to complete its U.S. pivotal clinical trial, to seek regulatory approvals, to fund research and development, and for working capital and general corporate purposes.

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease.  Its first generation continuous glucose monitoring (CGM) system, Eversense, includes a small sensor, smart transmitter and mobile application.  Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device.  After insertion, the sensor is designed to continually and accurately measure glucose levels.  Senseonics is based in Germantown, Maryland.